Problem viewing this email? Click here for our online version





junior staff member at Cold Spring Harbor, he worked on the development of technologies for the genetic manipulation of mammalian cells. Currently, Dr Conklin's laboratory uses functional genomic approaches to study mechanisms of cancer cell proliferation and survival. Much of the work involves high-throughput gene function studies to identify new genes important to human cancer cells followed by hypothesis-driven analysis of the "hits". His laboratory has been funded for several years to perform these studies on breast cancer.

Robert Corona, DO, Professor and Chair of Pathology, Upstate Medical University



Dr. Robert J. Corona is the John B Bernard Henry Professor of Pathology and Chairman of Pathology and Laboratory Medicine at Upstate Medical University. He is Clinical Chief of Pathology and Laboratory Medicine at University Hospital of Upstate Medical University, Residency Program Director and Director of Neuropathology. Dr. Corona also is Vice President of Innovation and Business Development and Director of the medical campus Biotechnology Accelerator Center. He is President of Upstate Pathologists Laboratories, LLC. Dr. Corona served as Vice President of Medical and Scientific Affairs and Chief Medical Officer at Welch Allyn, Inc. for 16 years. Prior to joining Welch Allyn, he was Physician Director of Medical Informatics, Laboratory Informatics and

Telemedicine at SUNY Upstate Medical University. While at Upstate, he founded CareNet, a medical informatics and telemedicine program that won the Smithsonian Award for Innovation in Medicine.

Shaun Lonergan, Vice President of Corporate Development, Metabolon



Shaun Lonergan is Vice President of Corporate Development at Metabolon, Inc. Prior to this role, he served as its Vice President and General Manager of Precision Medicine. Before joining Metabolon in 2014, Mr. Lonergan helped commercialize several major research and diagnostic instrument platforms and participated in or led the successful sale or public offerings of several companies while holding senior management positions at Boehringer Mannheim (Roche), Perceptive Biosystems (Thermo), Third Wave Technologies (Hologic), NimbleGen (Roche), 454 Life Sciences (Roche), Ibis Biosciences (Abbott Molecular) and Seegene, Inc. He also served as CEO of Nerites Corporation. Earlier, he was the clinical director at Oncology Laboratory, Inc. Mr. Lonergan earned his Master of Science degree in

microbiology from the University of Rhode Island.

Janet Paluh, PhD., Associate Professor of Nanobioscience, SUNY Polytechnic Institute



Dr. Janet L. Paluh is an Associate Professor in Nanobioscience at the State University of New York Polytechnic Institute in the Colleges of Nanoscale Science and Engineering (SUNY Poly CNSE) since 2010. She received her Ph.D. in Cancer Biology from Stanford University and completed her post-doctoral training at the University of California, Berkeley. Dr. Paluh is internationally recognized for her innovative research in multi-scale biological processes from self-assembling nanomachines to tissue microarchitectures applying human stem cell biology, nanotechnology and computational modeling towards biomedical advances. Her work includes identification of new cancer therapy targets and collaborations in understanding pathological

changes in neural networks during age onset neurodegeneration. She is actively involved in efforts to apply computational modeling and information theory to analysis of complex biological systems including the IEEE Standards Association P1906.1 working group on Recommended Practice for Nanoscale and Molecular Communication.

Stephen Eck, Vice President and Global Head of Oncology Medical Services, Astellas Pharma Global Development, Inc.



Dr. Eck is Vice President and Global Head of Oncology Medical Sciences at Astellas where he is responsible for the design and conduct of oncology studies in all phases of clinical development. Dr. Eck previously served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly where he was responsible for the clinical pharmacology components of drug development including both early phase clinical studies and late stage drug development studies. Dr. Eck also previously served in a variety of drug development leadership roles at Pfizer. Dr. Eck is a Hematologist/Oncologist with broad drug development experience in Oncology and Neuroscience and is a Fellow of the American Association for the Advancement of Science (pharmacology). He serves on the Scientific Advisory Board of

the ACGT Foundation (Greenwich, CT), on the Board of Trustees of the Keck Graduate School (Claremont, CA), and the Board of Directors of the Central Pennsylvania Clinic (Belleville, PA), a non-profit healthcare organization for children and adults with rare genetic diseases.





2 of 3



The Research Foundation for SUNY 35 State Street, Albany, NY 12207 To unsubscribe to this email listing, please <u>click here</u>

